Premium
Drug dosage and remission duration in childhood lymphocytic leukemia
Author(s) -
Pinkel Donald,
Hernandez Kathleen,
Borella Luis,
Holton Charlene,
Aur Rhomes,
Samoy Gregory,
Pratt Charles
Publication year - 1971
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197102)27:2<247::aid-cncr2820270202>3.0.co;2-c
Subject(s) - medicine , complete remission , chemotherapy , leukemia , acute lymphocytic leukemia , spontaneous remission , surgery , childhood leukemia , pediatrics , lymphoblastic leukemia , alternative medicine , pathology
Children with acute lymphocytic leukemia in complete remission were randomized between 2 combination chemotherapy schedules for continuation of their remissions. One group received full dosage of 4 antileukemic drugs, and the other received half dosage of the same compounds. Median durations of complete remission and of hematologic remission were longer in the full‐dosage than half‐dosage group. Four out of 21 patients in the full‐dosage group continue in their initial complete remission for 40 to 48 months and have been off treatment for 3 months to 1 year. Nine in the full‐dosage group and 4 in the half‐dosage group remain in continuous hematologic remission for 40 to 55 months. Review of results of previous combination chemotherapy studies of childhood lymphocytic leukemia at this hospital indicated a 17 per cent 5‐year leukemia ‐ free survival rate.